Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Quanterix Digital Immunoassay for Prostate Specific Antigen Improves Analytical Performance

July 21, 2011 By Bio-Medicine.Org

CAMBRIDGE, Mass., July 21, 2011 /PRNewswire/ — Quanterix
Corporation, an in-vitro diagnostics (IVD) company providing life
science researchers and IVD labs single molecule technology with
unprecedented sensitivity and precision, announced that the
analytical performance of AccuPSA™, a fifth-generation
digital immunoassay for Prostate Specific Antigen (PSA),
demonstrated a robust 2-log improvement in sensitivity over today’s
ultrasensitive third-generation assays for measuring PSA in
patients following radical prostatectomy.  The company’s
proprietary Single Molecule Array (SiMoA™) technology
platform combines both digital and analog detection in one
straightforward measurement, thereby broadening the range of
protein detection that can be acquired from a small sample size.
  Data will be presented at the American Association for
Clinical Chemistry (AACC) 2011 Annual Meeting held July 24-28 in
Atlanta, GA.  

“Because a radical prostatectomy removes the tissue responsible
for producing PSA, measuring this protein in patients following
surgery is very difficult with the assays available today,”
explains David Wilson Ph.D., Senior Director, Product Development
at Quanterix and lead author of the study.  “The 1000-fold
improvement in sensitivity from SiMoA enables us to accurately
measure PSA levels in all post radical prostatectomy patients
tested.   AccuPSA has the potential to provide precise and
reliable measurements of a patients’ PSA levels post surgery, which
could enable risk stratification for cancer recurrence based on a
single blood test.  This test could be a significant advance
for physicians to determine the right treatment and monitoring plan
going forward.”

These data are part of a follow-up retrospective pilot study
conducted by Quanterix that was designed to determine the ability
of the test to predict 5-year biochemical recurrence-free survival
following radical prostatectomy.  Data pres

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech